Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | CD74 | P04233 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzenesulfonamide SCHEMBL3255610 | 0.84 | CA1 (0.50) | ALDH1A1 | |
| SCHEMBL11207065 | 0.71 | MAOA (0.50) | ALDH1A1RAB9ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL3728814 | 0.68 | CALM1 (0.46) | ALDH1A1CALM1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL11428118 | 0.67 | FABP1 (0.50) | ALDH1A1SMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL7533150 | 0.67 | LTA4H (0.48) | ALDH1A1CALM1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL10388633 | 0.66 | MEN1 (0.52) | RAB9ASMN1; SMN2MEN1NPC1KMT2A | |
| SCHEMBL11330543 | 0.66 | KCNH2 (0.62) | ALDH1A1CALM1RAB9ASMN1; SMN2POLB | |
| SCHEMBL27072915 | 0.66 | CALM1 (0.55) | ALDH1A1CALM1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL289429 | 0.66 | — | — | |
| SCHEMBL345263 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 895 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3726994-B1 | BCA CONTROL OF STB | DANSTAR FERMENT AG (CH) | 2024-09-11 | — | — | EP | claimed |
| WO-2024140637-A1 | OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-07-04 | — | — | WO | claimed |
| WO-2024051766-A1 | MOLECULAR GLUE COMPOUND BASED ON CEREBLON PROTEIN DESIGN AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-03-14 | — | — | WO | claimed |
| WO-2024032689-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | claimed |
| WO-2023166485-A1 | FUNGICIDAL COMBINATIONS, MIXTURES AND COMPOSITIONS AND USES THEREOF | ADAMA MAKHTESHIM LTD. (IL) | 2023-09-07 | — | — | WO | claimed |
| WO-2023151635-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2023-08-17 | — | — | WO | claimed |
| WO-2023066350-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS | 标新生物医药科技(上海)有限公司 | 2023-04-27 | — | — | WO | claimed |
| WO-2023030170-A1 | PROTEIN DEGRADATION COMPOUND BASED ON NAMPT TARGET PROTEIN AND APPLICATION THEREOF | 标新生物医药科技(上海)有限公司 | 2023-03-09 | — | — | WO | claimed |
| US-20230051033-A1 | PESTICIDAL COMPOSITIONS AND RELATED METHODS | CJB APPLIED TECHNOLOGIES, LLC | 2023-02-16 | — | — | US | claimed |
| US-11083192-B2 | Fertilizer and agrochemical formulation | MITSUI CHEMICALS AGRO, INC. (JP) | 2021-08-10 | — | — | US | claimed |
| WO-2006014135-A1 | NOVEL PIPERIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR LIGANDS FOR TREATMENT OF DEPRESSION | ASTRAZENECA AB (SE) | 2006-02-09 | — | — | WO | claimed |
| WO-2006002022-A2 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF HYPERGLYCEMIA | IMMUSOL INCORPORATED (US) | 2006-01-05 | — | — | WO | claimed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | claimed |
| EP-1470131-A2 | AMINOPIPERIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2004-10-27 | — | — | EP | claimed |
| US-20040102432-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | claimed |
| JP-2004508355-A | — | — | 2004-03-18 | — | — | JP | claimed |
| WO-2003064431-A2 | AMINOPIPERIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2003-08-07 | — | — | WO | claimed |
| EP-1322611-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-07-02 | — | — | EP | claimed |
| US-6562844-B2 | Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | claimed |
| WO-2002020484-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102432-A1 | Chemical compounds | CCL11, HRH1, HRH4 | ALDH1A1 429/4885CALM1 4408/4885RAB9A 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.